The future of cancer immunotherapy is promising, with ongoing research aimed at overcoming current limitations. Combining different immunotherapeutic approaches, such as checkpoint inhibitors with cancer vaccines or CAR T-cell therapy, may enhance effectiveness. Additionally, identifying biomarkers for predicting response and developing strategies to modulate the tumor microenvironment are critical areas of research. Personalized immunotherapy, tailored to the unique genetic and antigenic profile of an individual's tumor, holds significant potential for improving outcomes.
